New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 — The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug …
WEBJun 11, 2024 — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
Experimental Alzheimer's drug donanemab outperforms Leqembi …
WEBJul 17, 2023 — In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July...
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 — The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
FDA approves donanemab, Eli Lilly’s treatment for early …
WEBJul 2, 2024 — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 — The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with...
Eli Lilly's donanemab, an Alzheimer's drug, gets FDA endorsement
WEBJun 10, 2024 — An FDA advisory panel endorsed the experimental Alzheimer's drug donanemab that studies showed slowed early stages of the fatal mind-robbing disease.
Alzheimer’s drug donanemab helps most when taken at earliest
WEBJul 17, 2023 — Like many others in the newest generation of Alzheimer’s drugs, donanemab is a monoclonal antibody that targets amyloid, a sticky, neuron-damaging protein, in the brains of people with dementia.
Eli Lilly expects FDA decision on Alzheimer's treatment …
WEBJul 17, 2023 — Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year ...